Skip to main content
Brock O'Neil
( out of 275 reviews )

Brock O'Neil, MD

Languages spoken: English, Italian

Clinical Locations

Primary Location

Brock O’Neil, MD is an associate professor in the Division of Urology at the University of Utah School of Medicine and the Huntsman Cancer Institute. His clinical practice focuses on the surgical treatment of genitourinary malignancies including prostate, bladder, kidney, adrenal, testicular, penile and urethral cancers. He is an experienced robotic, laparoscopic, endoscopic, and open surgeon. Dr O’Neil completed medical school at the University of Rochester, residency at the University of Utah, and fellowship in Urologic Oncology at Vanderbilt University.

Board Certification

American Board of Urology

Patient Rating

4.9 /5
( out of 275 reviews )

The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

The scale on which responses are measured is 1 to 5 with 5 being the best score.

Patient Comments

Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

HUNTSMAN CANCER CENTER

very professional

HUNTSMAN CANCER CENTER

Dr. O'Neill was honest and caring about my situation every step of the way. And his surgical skills kept my pain and recovery times to an absolute minimum. Quite a doctor and quite a team!

HUNTSMAN CANCER CENTER

All my questions were answered

HUNTSMAN CANCER CENTER

Now that we're on a schedule and not just figuring out what's wrong, this is a smooth process.

HUNTSMAN CANCER CENTER

My entire experience with Dr. O'Neil has been amazing. From his incredible skill as a surgeon to his excellent follow up and care.

HUNTSMAN CANCER CENTER

Dr. O'Neil and his staff gave me excellent care and advice. He was very personable and concerned for my best welfare.

HUNTSMAN CANCER CENTER

I realize that I requested an appointment that was somewhat last minute, but was scheduled to meet the doctor,and had another appointment 1 1/2 hours later that I needed to be on time for. I waited for the full 1 1/2 hours and never saw Doctor O'Neil.

HUNTSMAN CANCER CENTER

Dr. O'Neil is very friendly and is in no hurry to get to the next patient. I feel he genuinely cares about me. He is very knowledgeable and answered all my questions in a way I was able to understand. I feel very fortunate to have him as my doctor.

HUNTSMAN CANCER CENTER

Good

Brock O’Neil, MD is an associate professor in the Division of Urology at the University of Utah School of Medicine and the Huntsman Cancer Institute. His clinical practice focuses on the surgical treatment of genitourinary malignancies including prostate, bladder, kidney, adrenal, testicular, penile and urethral cancers. He is an experienced robotic, laparoscopic, endoscopic, and open surgeon. Dr O’Neil completed medical school at the University of Rochester, residency at the University of Utah, and fellowship in Urologic Oncology at Vanderbilt University.

Board Certification and Academic Information

Academic Departments Surgery -Associate Professor
Academic Divisions Urology
Board Certification
American Board of Urology

Education history

Undergraduate Exercise Science, Minor in Sociology - Brigham Young University B.S.
Professional Medical Doctor of Medicine with Distinction in Research - University of Rochester School of Medicine & Dentistry M.D.
Internship General Surgery - University of Utah Intern
Residency Urology - University of Utah Resident
Fellowship Urologic Oncology and Health Services Research - Vanderbilt University Fellow

Selected Publications

Journal Article

  1. Leiser CL, Taddie M, Hemmert R, Richards Steed R, VanDerslice JA, Henry K, Ambrose J, O'Neil B, Smith KR, Hanson H (2020). Spatial clusters of cancer incidence: analyzing 1940 census data linked to 1966-2017 cancer records. Cancer causes & control, 31(7), 609-615.
  2. Hanson HA, Leiser CL, O'Neil B, Martin C, Gupta S, Smith KR, Dechet C, Lowrance WT, Madsen MJ, Camp N (2020). Harnessing Population Pedigree Data and Machine Learning Methods to Identify Patterns of Familial Bladder Cancer Risk. Cancer epidemiology, biomarkers & prevention, 29(5), 918-926.
  3. Pasalic D, Barocas DA, Huang LC, Zhao Z, Koyama T, Tang C, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup AM, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Penson DF, Hoffman K (2021). Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer. Cancer, 127(11), 1912-1925.
  4. Hunt TC, Ambrose JP, Haaland B, Kawamoto K, Dechet CB, Lowrance WT, Hanson HA, O'Neil B (2021). Decision fatigue in low-value prostate cancer screening. Cancer, 127(18), 3343-3353.
  5. Laviana AA, Zhao Z, Huang LC, Koyama T, Conwill R, Hoffman K, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Penson DF, Barocas D (2020). Development and Internal Validation of a Web-based Tool to Predict Sexual, Urinary, and Bowel Function Longitudinally After Radiation Therapy, Surgery, or Observation. European urology, 78(2), 248-255.
  6. O'Neil BB, Graves AJ, Barocas DA, Chang SS, Penson DF, Resnick M (2015). Doing More for More: Unintended Consequences of Financial Incentives for Oncology Specialty Care. Journal of the National Cancer Institute, 108(2),
  7. Martin C, Leiser CL, O'Neil B, Gupta S, Lowrance WT, Kohlmann W, Greenberg S, Pathak P, Smith KR, Hanson H (2018). Familial Cancer Clustering in Urothelial Cancer: A Population-Based Case-Control Study. Journal of the National Cancer Institute, 110(5), 527-533.
  8. Nappi L, Thi M, Lum A, Huntsman D, Eigl BJ, Martin C, O'Neil B, Maughan BL, Chi K, So A, Black PC, Gleave M, Wyatt AW, Lavoie JM, Khalaf D, Bell R, Daneshmand S, Hamilton RJ, Leao RRN, Nichols C, Kollmannsberger (2019). Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum. Journal of clinical oncology, 37(33), 3090-3098.
  9. Mooney K, Titchener K, Haaland B, Coombs LA, O'Neil B, Nelson R, McPherson JP, Kirchhoff AC, Beck AC, Ward J (2021). Evaluation of Oncology Hospital at Home: Unplanned Health Care Utilization and Costs in the Huntsman at Home Real-World Trial. Journal of clinical oncology, 39(23), 2586-2593.
  10. O'Neil BB, Presson A, Gannon J, Stephenson RA, Lowrance W, Dechet CB, Tward JD, Myers JB, Brant W (2014). Climacturia after definitive treatment of prostate cancer. The Journal of urology, 191(1), 159-63.
  11. Sohn W, Graves AJ, Tyson MD, O'Neil BB, Chang SS, Ni D, Barocas DA, Penson DF, Resnick MJ (2016). An Empiric Evaluation of the Effect of Variation in Intensity of Follow-Up for Surgically Treated Renal Neoplasms: Estimating Value in Survivorship Care. The Journal of urology,
  12. O'Neil BB, Koyama T, Alvarez J, Conwill RM, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Hoffman RM, Kaplan SH, Stanford JL, Stroup AM, Paddock LE, Wu XC, Stephenson RA, Resnick MJ, Barocas DA, and Penson D (2015). The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples. The Journal of urology, 196,
  13. Hanson HA, Martin C, O'Neil B, Leiser CL, Mayer EN, Smith KR, Lowrance W (2019). The Relative Importance of Race Compared to Health Care and Social Factors in Predicting Prostate Cancer Mortality: A Random Forest Approach. The Journal of urology, 202(6), 1209-1216.
  14. Laviana AA, Hernandez A, Huang LC, Zhao Z, Koyama T, Conwill R, Hoffman K, Feurer ID, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Penson DF, Barocas D (2019). Interpretation of Domain Scores on the EPIC-How Does the Domain Score Translate into Functional Outcomes?. The Journal of urology, 202(6), 1150-1158.
  15. Martin C, Haaland B, Tward AE, Dechet C, Lowrance W, Stephenson RA, Hanson H, O'Neil (2019). Describing the Spectrum of Patient Reported Outcomes after Radical Prostatectomy: Providing Information to Improve Patient Counseling and Shared Decision Making. The Journal of urology, 201(4), 751-758.
  16. O'Neil B, Koyama T, Alvarez J, Conwill RM, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Hoffman RM, Kaplan SH, Stanford JL, Stroup AM, Paddock LE, Wu XC, Stephenson RA, Resnick MJ, Barocas DA, Penson D (2016). The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples. The Journal of urology, 195(2), 321-9.
  17. Reisz PA, Laviana AA, Zhao Z, Huang LC, Koyama T, Conwill R, Hoffman K, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Penson DF, Barocas D (2020). Assessing the Quality of Surgical Care for Clinically Localized Prostate Cancer: Results from the CEASAR Study. The Journal of urology, 204(6), 1236-1241.
  18. Stone BV, Laviana AA, Luckenbaugh AN, Huang LC, Zhao Z, Koyama T, Conwill R, Hoffman K, Joyce DD, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Penson DF, Barocas D (2021). Patient-Reported Financial Toxicity Associated with Contemporary Treatment for Localized Prostate Cancer. The Journal of urology, 205(3), 761-768.
  19. Hoffman KE, Penson DF, Zhao Z, Huang LC, Conwill R, Laviana AA, Joyce DD, Luckenbaugh AN, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Koyama T, Barocas D (2020). Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. JAMA, 323(2), 149-163.
  20. Jalali A, Martin C, Nelson RE, Vanneman ME, Martin BI, Cooney KA, Waitzman NJ, O'Neil (2020). Provider Practice Competition and Adoption of Medicare's Oncology Care Model. Medical care, 58(2), 154-160.
  21. Leiser CL, Anderson RE, Martin C, Hanson HA, O'Neil (2020). Combining Drive Time and Urologist Density to Understand Access to Urologic Care. Urology, 139, 78-83.
  22. O'Neil B, Tyson M, Graves AJ, Barocas DA, Chang SS, Penson DF, Resnick M (2017). The influence of provider characteristics and market forces on response to financial incentives. The American journal of managed care, 23(11), 662-667.
  23. Armstrong JM, Martin CR, Dechet C, Morton K, Evans D, Ambrose J, Maughan BL, O'Neil B, Lowrance (2020). 18F-fluciclovine PET CT detection of biochemical recurrent prostate cancer at specific PSA thresholds after definitive treatment. Urologic oncology, 38(7), 636.e1-636.e6.
  24. Huelster HL, Laviana AA, Joyce DD, Huang LC, Zhao Z, Koyama T, Hoffman KE, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg M, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Penson DF, Barocas D (2020). Radiotherapy after radical prostatectomy: Effect of timing of postprostatectomy radiation on functional outcomes. Urologic oncology, 38(12), 930.e23-930.e32.
  25. Dorff TB, O'Neil B, Hoffman KE, Lin DW, Loughlin KR, Dall'Era (2021). 25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology. Urologic oncology, 39(9), 521-527.
  26. Wallis CJD, Huang LC, Zhao Z, Penson DF, Koyama T, Conwill R, Tallman JE, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Barocas DA, Hoffman K (2021). Association between pelvic nodal radiotherapy and patient-reported functional outcomes through 5 years among men undergoing external-beam radiotherapy for prostate cancer: An assessment of the comparative effectiveness analysis of surgery and radiation (CEASAR) cohort. Urologic oncology, 40, 56.e1-56.e8.
  27. Tward JD, O'Neil B, Boucher K, Kokeny K, Lowrance WT, Lloyd S, Cannon D, Stephenson RA, Agarwal N, Farr T, Petragallo R, Sherar NZ, Kunz I, Hofer A, Courdy S, Shrieve DC, Dechet (2020). Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy. Clinical genitourinary cancer, 18(4), 274-283.e5.
  28. O'Neil B, Martin C, Kapron A, Flynn M, Kawamoto K, Cooney K (2018). Defining low-value PSA testing in a large retrospective cohort: Finding common ground between discordant guidelines. Cancer epidemiology, 56, 112-117.
  29. Oswald N, Lin T, Haaland B, Flynn M, Kawamoto K, Cooney KA, Lowrance W, Hanson HA, O'Neil (2020). Factors associated with appropriate and low-value PSA testing. Cancer epidemiology, 66, 101724.
  30. Tward JD, Poppe MM, Hitchcock YJ, O'Neil B, Albertson DJ, Shrieve D (2018). Demographics, stage distribution, and relative roles of surgery and radiotherapy on survival of persons with primary prostate sarcomas. Cancer medicine, 7(12), 6030-6039.
  31. Lange SM, Ambrose JP, Flynn MC, Lowrance WT, Hanson HA, O'Neil B (2021). Prostate-specific antigen testing among young men: an opportunity to improve value. Cancer medicine, 10(6), 2075-2079.
  32. O'Neil B, Maughan (2017). A More Common Massive Retroperitoneal Mass. JAMA surgery, 152(8), 802-803.
  33. Klett DE, O'Neil (2020). Transurethral Resection of a Bladder Tumor in Pregnancy: Decidual Reaction Bladder Endometriosis. Journal of endourology case reports, 6(3), 132-134.
  34. Greenberg SE, Hunt TC, Ambrose JP, Lowrance WT, Dechet CB, O'Neil BB, Tward J (2021). Clinical Germline Testing Results of Men With Prostate Cancer: Patient-Level Factors and Implications of NCCN Guideline Expansion. JCO precision oncology, 5,
  35. Vehawn J, O'Neil (2022). Identifying Top Talent to Improve Prostatectomy Sexual Outcomes: Is the Juice Worth the Squeeze?. JAMA surgery, 157(2), 144-145.
  36. Luckenbaugh AN, Wallis CJD, Huang LC, Wittmann D, Klaassen Z, Zhao Z, Koyama T, Laviana AA, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Hoffman KE, Penson DF, Barocas D (2022). Association Between Treatment for Localized Prostate Cancer and Mental Health Outcomes. The Journal of urology, 207, 101097JU0000000000002370.
  37. Slade AD, Cardinal JR, Martin CR, Presson AP, Allen CD, Lowrance WT, Dechet CB, O'Neil B (2021). Feasibility of wearable activity trackers in cystectomy patients to monitor for postoperative complications. Current urology, 15(4), 209-213.
  38. Lange SM, Choudry MM, Hunt TC, Ambrose JP, Haaland BA, Lowrance WT, Hanson HA, O'Neil B (2022). Impact of choosing wisely on imaging in men with newly diagnosed prostate cancer. Urologic oncology,
  39. Joyce DD, Wallis CJD, Huang LC, Hoffman KE, Zhao Z, Koyama T, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Penson DF, Barocas D (2022). The Association between Financial Toxicity and Treatment Regret in Men with Localized Prostate Cancer. JNCI cancer spectrum,
  40. Harper JB, Greenberg SE, Hunt TC, Cooney KA, O'Neil B (2022). Initial outcomes and insights from a novel high-risk prostate cancer screening clinic. The Prostate,
  41. De B, Pasalic D, Barocas DA, Wallis CJD, Huang LC, Zhao Z, Koyama T, Tang C, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Penson DF, Hoffman K (2022). Patient-Reported Outcomes after External Beam Radiotherapy with Low Dose-Rate Brachytherapy Boost versus Radical Prostatectomy for Localized Prostate Cancer: Five-Year Results from a Prospective Comparative Effectiveness Study. The Journal of urology, 101097JU0000000000002902.
  42. Hutten R, Khouri A, Parsons M, Tward A, Wilson T, Peterson J, Morrell G, Dechet C, O'Neil B, Schmidt B, Kokeny K, Lloyd S, Cannon D, Tward J, Sanchez A, Johnson (2022). The Clinical Significance of Maximum Tumor Diameter on MRI in Men Undergoing Radical Prostatectomy or Definitive Radiotherapy for Locoregional Prostate Cancer. Clinical genitourinary cancer, 20(6), e453-e459.
  43. Tallman JE, Wallis CJD, Huang LC, Zhao Z, Penson DF, Koyama T, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Barocas DA, Hoffman K (2022). Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer. Prostate cancer and prostatic diseases,
  44. Samora NL, Wallis CJD, Huang LC, Tallman JE, Zhao Z, Hoffman K, Morgans A, Cooperberg M, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Kaplan S, O'Neil B, Paddock LE, Stroup A, Wu XC, Koyama T, Penson DF, Barocas D (2022). Association between body mass index and localized prostate cancer management and disease-specific quality of life. BJUI compass, 4(2), 223-233.
  45. Harper J, Hunt T, Choudry M, Kapron AL, Cooney KA, Martin C, Ambrose J, O'Neil (2023). Clinician interest in clinical decision support for PSA-based prostate cancer screening. Urologic oncology, 41(3), 145.e17-145.e23.
  46. Tallman JE, Wallis CJD, Zhao Z, Huang LC, Penson DF, Koyama T, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Hoffman KE, Barocas D (2022). Prostate volume, baseline urinary function, and their association with treatment choice and post-treatment urinary function in men treated for localized prostate cancer. Prostate cancer and prostatic diseases,
  47. De B, Pasalic D, Barocas DA, Wallis CJD, Huang LC, Zhao Z, Koyama T, Tang C, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Penson DF, Hoffman K (2022). Reply by Authors. The Journal of urology, 208(6), 1239.
  48. O'Neil B, Hoffman KE, Koyama T, Alvarez JR, Conwill RM, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Kaplan SH, Hashibe M, Stanford JL, Stroup AM, Paddock LE, Chen V, Wu XC, Resnick MJ, Penson DF, Barocas D (2018). Patient Reported Comparative Effectiveness of Contemporary Intensity Modulated Radiation Therapy Versus External Beam Radiation Therapy of the Mid 1990s for Localized Prostate Cancer. Urology practice, 5(6), 471-479.
  49. Hu S, Chang CP, Snyder J, Deshmukh V, Newman M, Date A, Galvao C, Haaland B, Porucznik CA, Gren LH, Sanchez A, Lloyd S, O'Neil B, Hashibe (2023). Mental health outcomes in a population-based cohort of patients with prostate cancer. Journal of the National Cancer Institute, 116(3), 445-454.
  50. Huang D, Chang CE, Newman M, Deshmukh V, Snyder J, Date A, Galvao C, Lloyd S, Henry NL, O'Neil B, Hashibe (2023). Adverse health outcomes among rural prostate cancer survivors: A population-based study. Cancer epidemiology, 86, 102430.
  51. Nielsen S, O'Neil B, Chang CP, Mark B, Snyder J, Deshmukh V, Newman M, Date A, Galvao C, Henry NL, Lloyd S, Hashibe (2023). Determining the association of rurality and cardiovascular disease among prostate cancer survivors. Urologic oncology, 41(10), 429.e15-429.e23.
  52. O'Neil B, Dindinger-Hill K, Gill H, Coombs L, Haaland B, Ying J, Nelson RE, McPherson J, Kirchhoff AC, Ulrich CM, Huber J, Beck A, Mooney (2023). Cost and Utilization Outcomes in Huntsman at Home, a Novel Oncology Hospital at Home Program. Journal of the American Medical Directors Association, 25(4), 610-613.
  53. Lange SM, Vehawn J, Choudry MM, Ambrose JP, Cluff CM, Haaland BA, Paudel N, Chipman J, Hanson HA, O'Neil B (2023). Low-Value Prostate Cancer Screening Among Young Men With Private Insurance. Urology practice, 101097UPJ0000000000000461.
  54. Al Hussein Al Awamlh B, Wallis CJD, Penson DF, Huang LC, Zhao Z, Conwill R, Talwar R, Morgans AK, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, O'Neil BB, Koyama T, Hoffman KE, Barocas D (2024). Functional Outcomes After Localized Prostate Cancer Treatment. JAMA, 331(4), 302-317.
  55. Gore JL, Follmer K, Reynolds J, Nash M, Anderson CB, Catto JWF, Chamie K, Daneshmand S, Dickstein R, Garg T, Gilbert SM, Guzzo TJ, Kamat AM, Kates MR, Lane BR, Lotan Y, Mansour AM, Master VA, Montgomery JS, Morris DS, Nepple KG, O'Neil BB, Patel S, Pohar K, Porten SP, Riggs SB, Sankin A, Scarpato KR, Shore ND, Steinberg GD, Strope SA, Taylor JM, Comstock BA, Kessler LG, Wolff EM, Smith A (2023). Interruptions in bladder cancer care during the COVID-19 public health emergency. Urologic oncology,
  56. Hu S, Chang CP, Snyder J, Deshmukh V, Newman M, Date A, Galvao C, Porucznik CA, Gren LH, Sanchez A, Lloyd S, Haaland B, O'Neil B, Hashibe (2023). Comparing Active Surveillance and Watchful Waiting With Radical Treatment Using Machine Learning Models Among Patients With Prostate Cancer. JCO clinical cancer informatics, 7, e2300083.
  57. Dindinger-Hill K, Horns J, Ambrose J, Vehawn J, Choudry M, Hunt TC, Chipman J, Haaland B, Li J, Hanson HA, O'Neil (2024). Effect of Health Service Area on Primary Care Physician Provision of Low-Value Cancer Screening. Annals of internal medicine, 177(5), 583-591.
  58. Dindinger-Hill K, Hu S, Hickman A, Choudry M, Vehawn J, Snyder J, Deshmukh V, Newman M, Date A, Galvao C, Kohli M, O'Neil B, Schmidt B, Dechet C, Hashibe M, Sanchez (2024). Association of Baseline Pre-Diagnosis and Post-Diagnosis Obesity and Weight Change with Cardiovascular Risk and Survival Among Nonmetastatic Prostate Cancer Survivors. Clinical genitourinary cancer, 22(3), 102057.
  59. Choudry M, Dindinger-Hill K, Ambrose J, Horns J, Vehawn J, Gill H, Murray NZ, Hunt TC, Martin C, Haaland B, Chipman J, Hanson HA, O'Neil B (2024). Urban relatives ameliorate survival disparities for genitourinary cancer in rural patients. Cancer medicine, 13(5), e7058.
  60. Lopez AA, Awamlh BAHA, Huang LC, Zhao Z, Koyama T, Hoffman KE, Wallis CJD, Cavanaugh K, Talwar R, Morgans AK, Goodman M, Hamilton AS, Wu XC, Li J, O'Neil BB, Penson DF, Barocas D (2025). Patient-reported functional outcomes and treatment-related regret in Hispanic and Spanish-speaking men following prostate cancer treatment. Urologic oncology, 43(4), 271.e19-271.e28.
  61. Galarza Fortuna GM, Grass D, Maughan BL, Jain RK, Dechet C, Beck J, Schuetz E, Sanchez A, O'Neil B, Poch M, Li R, Lloyd S, Tward J, Phunrab T, Hawks JL, Swami U, Boucher KM, Agarwal N, Gupta (2025). Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT). Journal for immunotherapy of cancer, 13(3),
  62. Choudry MM, Murray N, Dindinger-Hill K, Ambrose J, Hunt TC, Horns J, Martin C, Haaland B, Lowrance W, Hanson HA, Matern R, Cartwright PC, O'Neil (2024). Genitourinary cancer and family: The reverberating psychological and cardiovascular effects of a genitourinary cancer diagnosis on first-degree relatives and spouses. Cancer, 130(23), 4061-4070.
  63. Nguyen DD, Barocas DA, Zhao Z, Huang LC, Koyama T, Al Hussein Ai Awamlh B, Penson DF, Morgans AK, Goodman M, Hamilton AS, Wu XC, Li J, Paddock LE, Stroup AM, O'Neil BB, Hoffman KE, Wallis CJ (2024). Association between smoking and prostate cancer survivors' long-term quality of life and function: an analysis of the CEASAR (Comparative Effectiveness Analysis of Surgery and Radiation) study. Journal of cancer survivorship,
  64. Chang Esther CP, Huang D, Lloyd S, Henry NL, O'Neil B, Hashibe (2025). Risks of adverse health outcomes among older rural prostate cancer survivors in the SEER-Medicare data. The Journal of rural health, 41(2), e70029.
  65. Ose DJ, Mark B, Ocier K, Adediran E, Taylor B, Svoboda K, Akerly W, O'Neil B, Henry NL, Hashibe (2025). Rural-Urban Disparities in Cancer Care-Analyzing Routinely Collected Patient-Reported Outcomes. A Cross-Sectional Study. Cancer medicine, 14(8), e70437.
  66. Lee H, Shen J, Fadlullah MZ, Neibling A, Hanson C, Ampaw E, Lin T, Larsen M, Lloyd J, Maughan BL, Swami U, Gupta S, Tward J, Johnson SB, O'Neil B, Schmidt B, Dechet CB, Haaland B, Wang L, Tan AC, Kohli (2025). Circulatory prostate cancer proteome landscapes and prognostic biomarkers in metastatic castrate resistant prostate cancer. Clinical proteomics, 22(1), 13.
  67. Gore JL, Wolff EM, Nash MG, Comstock BA, Gilbert SM, Chang SS, Chisolm S, MacLean DB, Wright JL, Kates MR, Pohar KS, Guzzo TJ, Bivalacqua TJ, Nepple KG, Montgomery JS, Scarpato KR, Woldu SL, Master VA, Chen DYT, Mossanen M, Daneshmand S, O'Neil BB, Tyson MD, Westerman ME, Kamat AM, Mansour AM, Chamie K, Riggs SB, Kukreja JB, Modi PK, Garg T, Peyton CC, Nix JW, Dickstein R, Gadzinski AJ, Sankin A, Shore ND, Lane BR, Bassett JC, Patel S, Morris DS, Macleod LC, Lee EK, Ritch CR, Follmer KM, Lee JR, Kim SM, Kessler LG, Smith AB, CISTO Collaborative grou (2025). Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer. Journal of clinical oncology, JCO2501324.
  68. Murray NZ, Lumpkins CY, Al Awamlh BAH, Wallis C, Diehl C, Barocas DA, Beskow LM, O'Neil (2025). Drivers Influencing Prostate Cancer Treatment Decision making - A Qualitative Analysis of Underrepresented Men across the US. Journal of racial and ethnic health disparities,
  69. Ou JY, Ramsay JM, Kaddas HK, VanDerslice JA, O'Neil B, García SM, Horne BD, Hanson H, Kirchhoff A (2025). Air Pollution and Cardiovascular Risks in Testicular Cancer Survivors: An Exploratory Case-Crossover Study. Journal of adolescent and young adult oncology, 15(1), 58-68.
  70. Galsky MD, Izadmehr S, Yu M, Curtis SD, Douville C, Popoli M, Ptak J, Dobbyn L, Silliman N, Chan KG, Dorff TB, Cetnar JP, O'Neil B, D'Souza A, Mamtani R, Kyriakopoulos CE, Brody R, Sadimin E, Mehrazin R, Chowell D, Sfakianos J, Daneshmand S, Pal SK, Bettegowda C, Kinzler KW, Papadopoulos N, Vogelstein B, Wang (2026). Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer. Proceedings of the National Academy of Sciences of the United States of America, 123(8), e2533449123.
  71. Wallis CJD, Zhao Z, Huang LC, Penson DF, Koyama T, Kaplan SH, Greenfield S, Luckenbaugh AN, Klaassen Z, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Hoffman KE, Barocas D (2022). Association of Treatment Modality, Functional Outcomes, and Baseline Characteristics With Treatment-Related Regret Among Men With Localized Prostate Cancer. JAMA oncology, 8(1), 50-59.

Review

  1. Lange S, O'Neil (2021). Increasing the value of PSA through improved implementation. Urologic oncology,

Conference Proceedings

  1. Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O'Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella L (2020). Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. Journal of clinical oncology, 38(24), 2798-2811.

Editorial

  1. Hunt TC, O'Neil B (2020). Leveraging Behavioral Economics to Reduce Low-value Prostate Cancer Screening. European urology, 77(4), 400-402.
  2. Filon M, O'Neil (2025). Can We Be Less Active in Prostate Cancer Surveillance?. The Journal of urology, 213(1), 3-4.
  3. Tingey S, Gangwish D, O'Neil (2026). Data Grow in Support of Micro-Ultrasound for Prostate Cancer Diagnosis. The Journal of urology, 215(2), 142-143.

Letter

  1. Hanson HA, Martin C, Leiser CL, O'Neil B, Smith K (2018). Response to K. Hemminki et al. Journal of the National Cancer Institute, 110(11), 1279.
  2. O'Neil B, Lowrance WT, Heilbrun M (2017). PET Scans With 18F-Fluorodeoxyglucose to Diagnose Adrenal Tumors. JAMA, 318(16), 1614.

Abstract

  1. Martin C, O'Neil BB, Kapron A, Kawamoto K, Lowrance W, Flynn M, Cooney (2018). Rate of Discordant PSA Testing Among Varied Guidelines: Identifying Targetable Inefficiencies in Our Health System. The Journal of urology, 199(4),
  2. Hanson H, Leiser C, Martin C, O'Neil BB, Lowrance W, Alter O, Gupta S, Kohlman W, Greenberg W, Smith K, Camp (2018). Redefining the Bladder Cancer Phenotype Using Patterns of Familial Risk. The Journal of urology, 199(4),
  3. O'Neil B, Anderson R, Martin C, Leiser C, Hanson (2019). A Novel Approach to Identify Disparities in Access to Urologic Care Based Upon Driving TIme.
  4. Jalali A, Nelson R, Vanneman M, Martin C, Martin B, Waitzman N, O'Neil B (2018). Provider Practice Competition and Adoption of Medicare's Oncology Care Model.
  5. Martin CM, O'Neil BB, Kapron A, Flynn M, Kawamoto K, Lowrance WT, Cooney (2017). Measuring PSA Screening Quality at the Health System Level: Potental Areas for Improvement.
  6. Greenberg S, Tward J, Cooney K, Pappas L, O'Neil (2019). Germline genetic testing in men with prostate cancer: clinical characteristics and testing outcomes in a newly indicated population.
  7. Armstrong J, Martin C, O'Neil B, Dechet C, Morton K, Lowrance (2018). Fluciclovine PET CT Detection of Biochemical Recurrent Prostate Cancer at Specific PSA Thresholds After Definitive Treatment.